Shares of Egalet Corporation (NASDAQ:EGLT) last traded at $2.48. (NASDAQ:EGLT) performance year to date is -67.58%. The 200 day simple moving average is -58.03%. The 200 SMA is considered a major indicator by market analysts and traders for determining the long-term trend. The price in the market that coincides with the 200 day SMA is recognized as a key support when price moves above the 200 day SMA or resistance when price drops below the same.
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in the developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications. Its principal product candidate consist of Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain and Egalet-003 which are in pre-clinical trials. Egalet Corporation is based in City of Westminster, United Kingdom.
Egalet Corporation (NASDAQ:EGLT) has been in the buzz for all the right reasons.
The Barchart Technical Opinion rating is a 80% Sell with a Weakest short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend. The market is approaching oversold territory. Be watchful of a trend reversal.
The Exponential Moving Average is similar to a simple moving average but it uses a weighting element that exponentially drops from the recent data point. EMA analysis assesses the short term,5 days and 13 days, intermediate term that is 20 days and long-term 50 days EMA. These EMAs will give bullish indications when moving above trailing EMAs and below the latest price and vice versa. EMA alerts comprise crossovers that is the 5 day EMA crosses below/above the 20 day EMA and EMA convergences, 5 day EMA comparable to 13 day EMA. Currently, the 5 day EMA 2.39 is lower than the last trade price suggesting a short term bullish pattern building up. Long term, the 50 day EMA 3.54 is higher than current trading price depicting a bearish pattern..
The relative strength index is a momentum oscillator that can measure the magnitude of stock price and velocity changes. Momentum is computed as the ratio of plus price changes to negative price changes. The RSI assessment compares the prevailing RSI against oversold (30), overbought (70) and neutral (50) conditions. Alerts will apprise you when stocks retreat from overbought/oversold levels or breakthrough neutral (50). The current RSI is 33.97 suggesting a bearish price action.
Egalet Corporation (NASDAQ:EGLT) is all set to report its earnings on May 10. As per Zack’s analyst scores, Egalet Corporation (NASDAQ:EGLT) currently has a mean brokerage rating of 1. On a scale of 1-5, a rating of 1 or 2 would imply a buy, and a rating of 4 or 5 would indicate a sell recommendation. A rating of 3 would represent a hold on the equity. The consensus target price on (NASDAQ:EGLT) is $10.5 with a high of $14 and a low of $8.
As such, while we consider Egalet Corporation (NASDAQ:EGLT) represents a enthralling growth story open to several attractive markets, it would be fascinating to see how it works for long-term shareholders.
Egalet Corporation (NASDAQ:EGLT) (“Egalet”), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced it has received a U.S. patent for its proprietary Guardian(TM) Technology tablet architecture used to create precise delivery of combination products with immediate-, delayed- and/or extended-release properties.